The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes

Hee Jun Kim, Hyeon Yeong Ahn, Jung Hyun Kwak, Dong Yeob Shin, Young In Kwon, Chen Gum Oh, Jong Ho Lee

Research output: Contribution to journalArticle

19 Citations (Scopus)

Abstract

We aimed to evaluate the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. This study was a randomized, double-blind, placebo-controlled clinical trial. Subjects with prediabetes were randomly assigned to the GO2KA1 intervention group or the placebo group for 12 weeks. We assessed the serum levels of glucose, insulin, and C-peptide by a 2 hour value in the 75 g oral glucose tolerance test (OGTT), HbA1c, pro-inflammatory cytokines, and plasma adiponectin at baseline and after the 12 week intervention. The treatment group showed a significant decrease in the serum glucose level at 30 min (p = 0.013) and at 60 min (p = 0.028). The change of the serum glucose level at 60 min was significant in the treatment group compared with the placebo group (p = 0.030). Also, the plasma level of HbA1c (p = 0.023) and the pro-inflammatory cytokines (IL-6 and TNF-α) were reduced and plasma adiponectin was increased in the GO2KA1 intervention group after the 12 week treatment. However, the placebo group did not show any significant changes in these biomarkers. In subjects with prediabetes, 12 week supplement with GO2KA1 may help control postprandial glucose compared with control.

Original languageEnglish
Pages (from-to)2662-2669
Number of pages8
JournalFood and Function
Volume5
Issue number10
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

Prediabetic State
Chitosan
chitosan
Oligosaccharides
oligosaccharides
placebos
Glucose
glucose
Placebos
glycohemoglobin
adiponectin
Adiponectin
cytokines
Serum
Cytokines
C-Peptide
Controlled Clinical Trials
Glucose Tolerance Test
interleukin-6
clinical trials

All Science Journal Classification (ASJC) codes

  • Food Science

Cite this

Kim, Hee Jun ; Ahn, Hyeon Yeong ; Kwak, Jung Hyun ; Shin, Dong Yeob ; Kwon, Young In ; Oh, Chen Gum ; Lee, Jong Ho. / The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. In: Food and Function. 2014 ; Vol. 5, No. 10. pp. 2662-2669.
@article{a668de0238ac4679b61e719d2c570669,
title = "The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes",
abstract = "We aimed to evaluate the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. This study was a randomized, double-blind, placebo-controlled clinical trial. Subjects with prediabetes were randomly assigned to the GO2KA1 intervention group or the placebo group for 12 weeks. We assessed the serum levels of glucose, insulin, and C-peptide by a 2 hour value in the 75 g oral glucose tolerance test (OGTT), HbA1c, pro-inflammatory cytokines, and plasma adiponectin at baseline and after the 12 week intervention. The treatment group showed a significant decrease in the serum glucose level at 30 min (p = 0.013) and at 60 min (p = 0.028). The change of the serum glucose level at 60 min was significant in the treatment group compared with the placebo group (p = 0.030). Also, the plasma level of HbA1c (p = 0.023) and the pro-inflammatory cytokines (IL-6 and TNF-α) were reduced and plasma adiponectin was increased in the GO2KA1 intervention group after the 12 week treatment. However, the placebo group did not show any significant changes in these biomarkers. In subjects with prediabetes, 12 week supplement with GO2KA1 may help control postprandial glucose compared with control.",
author = "Kim, {Hee Jun} and Ahn, {Hyeon Yeong} and Kwak, {Jung Hyun} and Shin, {Dong Yeob} and Kwon, {Young In} and Oh, {Chen Gum} and Lee, {Jong Ho}",
year = "2014",
month = "1",
day = "1",
doi = "10.1039/c4fo00469h",
language = "English",
volume = "5",
pages = "2662--2669",
journal = "Food and Function",
issn = "2042-6496",
publisher = "Royal Society of Chemistry",
number = "10",

}

The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. / Kim, Hee Jun; Ahn, Hyeon Yeong; Kwak, Jung Hyun; Shin, Dong Yeob; Kwon, Young In; Oh, Chen Gum; Lee, Jong Ho.

In: Food and Function, Vol. 5, No. 10, 01.01.2014, p. 2662-2669.

Research output: Contribution to journalArticle

TY - JOUR

T1 - The effects of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes

AU - Kim, Hee Jun

AU - Ahn, Hyeon Yeong

AU - Kwak, Jung Hyun

AU - Shin, Dong Yeob

AU - Kwon, Young In

AU - Oh, Chen Gum

AU - Lee, Jong Ho

PY - 2014/1/1

Y1 - 2014/1/1

N2 - We aimed to evaluate the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. This study was a randomized, double-blind, placebo-controlled clinical trial. Subjects with prediabetes were randomly assigned to the GO2KA1 intervention group or the placebo group for 12 weeks. We assessed the serum levels of glucose, insulin, and C-peptide by a 2 hour value in the 75 g oral glucose tolerance test (OGTT), HbA1c, pro-inflammatory cytokines, and plasma adiponectin at baseline and after the 12 week intervention. The treatment group showed a significant decrease in the serum glucose level at 30 min (p = 0.013) and at 60 min (p = 0.028). The change of the serum glucose level at 60 min was significant in the treatment group compared with the placebo group (p = 0.030). Also, the plasma level of HbA1c (p = 0.023) and the pro-inflammatory cytokines (IL-6 and TNF-α) were reduced and plasma adiponectin was increased in the GO2KA1 intervention group after the 12 week treatment. However, the placebo group did not show any significant changes in these biomarkers. In subjects with prediabetes, 12 week supplement with GO2KA1 may help control postprandial glucose compared with control.

AB - We aimed to evaluate the effect of chitosan oligosaccharide (GO2KA1) supplementation on glucose control in subjects with prediabetes. This study was a randomized, double-blind, placebo-controlled clinical trial. Subjects with prediabetes were randomly assigned to the GO2KA1 intervention group or the placebo group for 12 weeks. We assessed the serum levels of glucose, insulin, and C-peptide by a 2 hour value in the 75 g oral glucose tolerance test (OGTT), HbA1c, pro-inflammatory cytokines, and plasma adiponectin at baseline and after the 12 week intervention. The treatment group showed a significant decrease in the serum glucose level at 30 min (p = 0.013) and at 60 min (p = 0.028). The change of the serum glucose level at 60 min was significant in the treatment group compared with the placebo group (p = 0.030). Also, the plasma level of HbA1c (p = 0.023) and the pro-inflammatory cytokines (IL-6 and TNF-α) were reduced and plasma adiponectin was increased in the GO2KA1 intervention group after the 12 week treatment. However, the placebo group did not show any significant changes in these biomarkers. In subjects with prediabetes, 12 week supplement with GO2KA1 may help control postprandial glucose compared with control.

UR - http://www.scopus.com/inward/record.url?scp=84907852136&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84907852136&partnerID=8YFLogxK

U2 - 10.1039/c4fo00469h

DO - 10.1039/c4fo00469h

M3 - Article

C2 - 25222285

AN - SCOPUS:84907852136

VL - 5

SP - 2662

EP - 2669

JO - Food and Function

JF - Food and Function

SN - 2042-6496

IS - 10

ER -